Biomarker discovery for colon cancer using a 761 gene RT-PCR assay.
BACKGROUND
Reverse transcription PCR (RT-PCR) is widely recognized to be the gold standard method for quantifying gene expression. Studies using RT-PCR technology as a discovery tool have historically been limited to relatively small gene sets compared to other gene expression platforms such as microarrays. We have recently shown that TaqMan RT-PCR can be scaled up to profile expression for 192 genes in fixed paraffin-embedded (FPE) clinical study tumor specimens. This technology has also been used to develop and commercialize a widely used clinical test for breast cancer prognosis and prediction, the Onco typeDX assay. A similar need exists in colon cancer for a test that provides information on the likelihood of disease recurrence in colon cancer (prognosis) and the likelihood of tumor response to standard chemotherapy regimens (prediction). We have now scaled our RT-PCR assay to efficiently screen 761 biomarkers across hundreds of patient samples and applied this process to biomarker discovery in colon cancer. This screening strategy remains attractive due to the inherent advantages of maintaining platform consistency from discovery through clinical application.


RESULTS
RNA was extracted from formalin fixed paraffin embedded (FPE) tissue, as old as 28 years, from 354 patients enrolled in NSABP C-01 and C-02 colon cancer studies. Multiplexed reverse transcription reactions were performed using a gene specific primer pool containing 761 unique primers. PCR was performed as independent TaqMan reactions for each candidate gene. Hierarchal clustering demonstrates that genes expected to co-express form obvious, distinct and in certain cases very tightly correlated clusters, validating the reliability of this technical approach to biomarker discovery.


CONCLUSIONS
We have developed a high throughput, quantitatively precise multi-analyte gene expression platform for biomarker discovery that approaches low density DNA arrays in numbers of genes analyzed while maintaining the high specificity, sensitivity and reproducibility that are characteristics of RT-PCR. Biomarkers discovered using this approach can be transferred to a clinical reference laboratory setting without having to re-validate the assay on a second technology platform.
Clark-Langone
Kim M
KM
Genomic Health, Inc, Redwood City, CA, USA. klangone@genomichealth.com
Wu
Jenny Y
JY
Sangli
Chithra
C
Chen
Angela
A
Snable
James L
JL
Nguyen
Anhthu
A
Hackett
James R
JR
Baker
Joffre
J
Yothers
Greg
G
Kim
Chungyeul
C
Cronin
Maureen T
MT
D014408:Biomarkers, Tumor / Q000235:genetics*; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000235:genetics*; D018076:DNA, Complementary; D006801:Humans; D005810:Multigene Family; D015203:Reproducibility of Results; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*; D013698:Templates, Genetic; D014158:Transcription, Genetic
D014408:Biomarkers, Tumor; D018076:DNA, Complementary
Am J Pathol. 2004 Nov;165(5):1799-807
15509548
J Biol Chem. 2003 Jan 10;278(2):1372-9
12393869
J Clin Oncol. 1990 Sep;8(9):1466-75
2202789
Curr Opin Cell Biol. 1994 Oct;6(5):717-25
7530463
Nature. 2004 Nov 18;432(7015):332-7
15549095
Clin Chem. 2004 Dec;50(12):2384-6
15563488
N Engl J Med. 2004 Dec 30;351(27):2817-26
15591335
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3738-43
15701700
Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G2-7
15961883
Clin Cancer Res. 2005 Jul 15;11(14):5128-39
16033827
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8623-31
16361546
J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34
12775774
Am J Pathol. 2004 Jan;164(1):35-42
14695316
Cancer Res. 2003 Dec 15;63(24):8791-812
14695196
PLoS Biol. 2004 Feb;2(2):E7
14737219
Nat Genet. 2006 Apr;38(4):421-30
16518402
Nat Rev Cancer. 2006 May;6(5):392-401
16572188
Clin Chem. 2007 Jun;53(6):1084-91
17463177
J Clin Oncol. 2004 May 1;22(9):1564-71
15051756
Cancer Res. 1999 Nov 15;59(22):5656-61
10582678
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
Am J Pathol. 2001 Oct;159(4):1231-8
11583950
Mol Biol Cell. 2002 Jun;13(6):1977-2000
12058064
N Engl J Med. 2002 Jun 20;346(25):1937-47
12075054
J Natl Cancer Inst. 1988 Mar 2;80(1):30-6
3276901